Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis
- Guy Jerusalem
- , Yeon Hee Park
- , Toshinari Yamashita
- , Sara A. Hurvitz
- , Shanu Modi
- , Fabrice Andre
- , Ian E. Krop
- , Xavier Gonzàlez Farré
- , Benoit You
- , Cristina Saura
- , Sung Bae Kim
- , Cynthia R. Osborne
- , Rashmi K. Murthy
- , Lorenzo Gianni
- , Toshimi Takano
- , Yali Liu
- , Jillian Cathcart
- , Caleb Lee
- , Christophe Perrin
- University of Liege
- Kanagawa Cancer Center Research Institute
- University of California at Los Angeles
- Memorial Sloan-Kettering Cancer Center
- Gustave Roussy
- Yale University
- Hospital General de Catalunya
- Universite Claude Bernard Lyon 1
- Vall d'Hebron Institute of Oncology
- University of Ulsan
- McKesson Specialty Health
- Texas Oncology
- University of Texas MD Anderson Cancer Center
- Infermi Hospital
- Japanese Foundation for Cancer Research
- Daiichi Sankyo Company, Limited
- Centre Georges-François Leclerc
Research output: Contribution to journal › Article › peer-review
88
Link opens in a new tab
Scopus
citations